Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →To get a GLP-1 prescription online, complete a telehealth intake with a licensed clinician, share your medical history, height, weight, medicines, and labs if available, then complete a video, phone, or asynchronous visit. If you meet criteria, the clinician may prescribe a branded or compounded option and route it to a pharmacy [1][2][12].
What is a GLP-1, and why is it prescription-only?
GLP-1 medications are prescription drugs that act on hormone pathways involved in appetite, blood sugar, and digestion. They are prescription-only because they can cause side effects, interact with other medicines, and may be unsafe for people with certain endocrine, pancreas, gallbladder, kidney, or pregnancy-related risks [1][2][3].
A GLP-1 receptor agonist, such as semaglutide, copies part of the action of the body’s GLP-1 hormone. A GIP/GLP-1 receptor agonist, such as tirzepatide, acts on both GIP and GLP-1 receptors [1][2]. In clinical trials, these medicines were linked with weight loss over 68 to 72 weeks, but individual results vary, and side effects such as nausea, vomiting, diarrhea, constipation, abdominal pain, and gallbladder problems were also reported [9][10].
Wegovy (semaglutide, a GLP-1 receptor agonist; also available as compounded semaglutide through some licensed 503A pharmacies when legally permitted) is FDA-approved for chronic weight management and for reducing certain cardiovascular risks in adults with obesity or overweight and established cardiovascular disease [1]. Zepbound (tirzepatide, a GIP/GLP-1 receptor agonist; also available as compounded tirzepatide through some licensed 503A pharmacies when legally permitted) is FDA-approved for chronic weight management and certain obstructive sleep apnea uses in adults with obesity [2].
Who is eligible for a GLP-1 prescription?
Eligibility for GLP-1 treatment depends on the medication, your BMI, your health conditions, and your safety risks. FDA labels for Wegovy, Zepbound, and Saxenda include adults with BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol [1][2][3].
FDA BMI and comorbidity criteria
For chronic weight management, Wegovy, Zepbound, and Saxenda are labeled as additions to a reduced-calorie diet and increased physical activity in people who meet BMI criteria [1][2][3]. In the STEP 1 trial, participants received semaglutide 2.4 mg once weekly, and in SURMOUNT-1, participants received tirzepatide 5 mg, 10 mg, or 15 mg once weekly; both trials studied adults with obesity or overweight, individual results varied, and gastrointestinal side effects were common [9][10].
Who should not take a GLP-1
A clinician will screen for contraindications and cautions. Wegovy, Zepbound, and Saxenda labels include boxed warnings about thyroid C-cell tumors seen in rodents and contraindications for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1][2][3].
You may need extra review if you have a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney problems related to dehydration, diabetic retinopathy, eating-disorder concerns, pregnancy, or plans to become pregnant [1][2][3][4][5]. These medicines may support weight loss for some eligible people, but they also require monitoring for side effects and for whether the benefit is worth the risk [9][10][11].
What are the steps to get a GLP-1 prescription online?
Getting a GLP-1 online usually means completing a medical intake, clinician review, prescription decision, pharmacy routing, and follow-up. Federal telehealth policy allows many care steps to happen remotely, but the clinician must still follow state law, medical standards, and prescription rules during each online visit [12].
Step 1: Complete an online health intake
The intake usually asks for height, weight, BMI, medical conditions, allergies, current medications, prior weight-loss treatments, pregnancy status, and pharmacy preferences. Some clinicians also request recent labs, such as A1C, kidney function, liver tests, lipids, or thyroid-related history, because GLP-1 labels include safety warnings that require medical review [1][2][3][4][5].
Step 2: Telehealth visit with a licensed clinician
Your visit may be synchronous, meaning live video or phone, or asynchronous, meaning secure messages reviewed by a clinician. Either way, the prescriber should confirm that the medication is appropriate, discuss side effects, explain alternatives, and answer questions before prescribing [12].
Step 3: Prescription and pharmacy routing
If a GLP-1 is appropriate, the clinician may route a prescription to a retail pharmacy, mail-order pharmacy, insurance-preferred pharmacy, or licensed compounding pharmacy. A 503A compounding pharmacy prepares patient-specific prescriptions under state pharmacy oversight and federal compounding rules, but compounded GLP-1 products are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before dispensing [8].
Step 4: Delivery and follow-up
Follow-up matters because GLP-1 medicines can cause nausea, vomiting, diarrhea, constipation, reflux, abdominal pain, dehydration, gallbladder problems, and rare serious events such as pancreatitis [1][2][3]. A safe online provider should give you a way to report side effects, adjust the care plan, and ask whether the medication still fits your goals and risks.
Which GLP-1 medications can you actually get online?
Online GLP-1 prescriptions may include FDA-approved branded medications, diabetes medications used only for their labeled diabetes indication, or compounded options when legally permitted. The right path depends on diagnosis, insurance, availability, cost, and safety screening, not just whether a site can ship medication within a few days [1][2][4][5][8].
Branded: Wegovy, Zepbound, Saxenda, and Foundayo
Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in people who meet label criteria [1][2]. Saxenda (liraglutide, a GLP-1 receptor agonist) is also FDA-approved for chronic weight management, though its FDA label describes once-daily injection rather than once-weekly injection [3]. These medicines may support weight loss for eligible patients, but common side effects include gastrointestinal symptoms, and contraindications must be reviewed [1][2][3].
Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes indications, not chronic weight management [4][5]. Using Ozempic or Mounjaro only for weight loss is off-label and should be discussed neutrally with a clinician; it is not the same as using an FDA-labeled weight-management product [4][5].
Orforglipron is an oral GLP-1 receptor agonist that has been studied for weight management and type 2 diabetes in clinical trials, with gastrointestinal side effects reported in published research [13]. If a brand such as Foundayo is available in your market, confirm its current FDA label, indication, safety information, and pharmacy availability directly through FDA resources and your clinician before making decisions.
Compounded semaglutide and tirzepatide via 503A pharmacies
Compounded semaglutide via a 503A pharmacy and compounded tirzepatide via a 503A pharmacy are not FDA-approved. FDA has warned that compounded versions may pose risks when they use unapproved salt forms, have dosing errors, or are made outside appropriate legal and quality standards [6][8].
FDA shortage status can affect whether pharmacies may compound copies of commercially available GLP-1 drugs. Because the FDA Drug Shortages list changes, patients should verify current status on FDA.gov and ask the prescriber which pharmacy will dispense the medication [7][8].
How much does an online GLP-1 prescription cost?
GLP-1 cost online can include a clinician visit, membership or care fee, lab work, the medication itself, shipping, and follow-up. Pricing and insurance coverage change often, so verify current costs directly with the provider, insurer, and pharmacy before you start, especially if a quoted price is valid for only 30 days.
| Path | What you may pay for | What to check | Safety note |
|---|---|---|---|
| Insurance-covered branded GLP-1 | Copay, deductible, prior authorization, labs, visits | Coverage for Wegovy, Zepbound, or Saxenda; BMI rules; step therapy | Use must match plan and label criteria; side effects and contraindications still apply [1][2][3] |
| Cash-pay branded GLP-1 | Full pharmacy price, visit fees, follow-up | Manufacturer price, savings programs, pharmacy stock | Higher cost does not remove the need for clinician monitoring [1][2] |
| Compounded semaglutide or tirzepatide | Medication, supplies, shipping, clinician care | 503A pharmacy name, prescription-specific dispensing, testing practices, current FDA shortage status | Not FDA-approved; FDA has warned about dosing errors and unapproved salt forms [6][8] |
| Diabetes-labeled GLP-1 | Copay or cash price for Ozempic or Mounjaro | Whether you have a labeled diabetes indication | Ozempic and Mounjaro are not FDA-approved for chronic weight management [4][5] |
Some telehealth programs publish separate prices for the visit, membership, and medication, while others bundle parts of care. Read the terms closely, because a low advertised visit fee may not include the medication, lab work, prior authorization help, or follow-up.
Insurance vs. cash-pay vs. compounded: which path fits you?
Insurance, cash-pay, and compounded GLP-1 paths each have trade-offs. Insurance may lower medication cost but often requires prior authorization; cash-pay can be simpler but expensive; compounded options may be available through licensed pharmacies when legally permitted but are not FDA-approved, and pharmacy status should be checked each time a prescription is filled [7][8].
- Insurance may fit if your plan covers anti-obesity medication and you meet BMI and comorbidity criteria on the FDA label [1][2][3].
- Cash-pay branded medication may fit if coverage is denied or you prefer not to use insurance, but you should confirm the full pharmacy price before starting.
- Compounded GLP-1 medication may fit some patients when a licensed clinician determines it is appropriate and a licensed 503A pharmacy can legally dispense it; these products are not FDA-approved [8].
- Diabetes-labeled medicines such as Ozempic and Mounjaro should be used according to their FDA-approved diabetes labels unless a clinician makes an off-label decision after reviewing risks and alternatives [4][5].
How long does it take to get the prescription and medication?
Online GLP-1 timelines vary by provider, state, insurance, pharmacy stock, and whether labs or prior authorization are needed. A simple cash-pay or compounded path may move faster than an insurance path, but safe prescribing still requires clinical review, side-effect counseling, and a way to follow up after the first prescription [8][12].
Insurance prior authorization can add time because the plan may ask for BMI, diagnosis codes, prior treatments, or proof of weight-related conditions. Pharmacy delays can also happen when branded GLP-1 products are out of stock or when shortage status changes [7].
How can you get a GLP-1 through an online provider?
A licensed telehealth provider should review your intake, explain branded and compounded options, prescribe only when appropriate, and route the prescription to a qualified pharmacy. Chia is one option for clinician-reviewed access to compounded GLP-1 treatment through US 503A pharmacy partners, with eligibility decided by a licensed clinician rather than by an online quiz alone [8][12].
3-min quiz
Explore clinician-reviewed GLP-1 options
If you are considering treatment, a licensed clinician can review your history, eligibility, risks, and pharmacy options before any prescription decision is made.
How can you spot an unsafe online GLP-1 provider?
Unsafe online GLP-1 sellers often skip medical review or hide where the medication comes from. FDA has warned patients about compounded semaglutide dosing errors, unapproved salt forms, and products sold outside normal pharmacy standards, and a safe provider should be able to name the dispensing pharmacy before payment [6][8].
- No licensed clinician reviews your medical history before payment.
- The site promises guaranteed weight loss or says there are no side effects.
- The product is labeled “research use only,” “not for human use,” or sold without a prescription.
- The seller will not name the dispensing pharmacy or confirm it is licensed.
- The product claims to be FDA-approved when it is actually compounded.
- The site gives one-size-fits-all dosing instructions without follow-up.
- The seller ships loose vials or syringes without clear labeling, storage instructions, or pharmacist access.
A safer provider should explain the medication’s FDA status, screen for contraindications, give side-effect guidance, and offer follow-up. If a compounded product is discussed, the provider should clearly say it is not FDA-approved and should identify the dispensing pharmacy [6][8].
Not always. Many patients can complete a telehealth visit by video, phone, or secure asynchronous messaging, depending on state law, the clinician’s rules, and the medication. A licensed clinician still has to review your history and decide whether prescribing is appropriate [12].
Yes, a licensed clinician may prescribe Wegovy or Zepbound online if you meet label criteria and do not have contraindications. The prescription is usually sent to a retail, mail-order, or specialty pharmacy [1][2].
Ozempic is FDA-approved for type 2 diabetes indications, not chronic weight management. Using it only for weight loss is off-label and should be discussed with a licensed clinician who can explain labeled alternatives, risks, side effects, and coverage issues [4].
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved. They may be available through licensed 503A pharmacies when legally permitted, but FDA does not review compounded drugs for safety, effectiveness, or quality before dispensing [6][8].
For FDA-labeled chronic weight management, Wegovy, Zepbound, and Saxenda labels include BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition. A clinician must also review contraindications and whether the medication is appropriate for you [1][2][3].
Sometimes. Coverage depends on your plan, diagnosis, BMI, prior authorization rules, and whether the medication is on your formulary. You should verify coverage with your insurer and pharmacy before starting because costs change often.
Timing varies. It depends on whether the clinician needs labs, whether insurance requires prior authorization, and whether the pharmacy has the medication in stock. A safe provider should not skip medical screening just to move faster [12].
Yes. AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health; a licensed clinician still makes the prescribing decision after reviewing eligibility, risks, and medical history.
3-min quiz
Talk with a licensed clinician
A clinical review can help you understand whether a branded or compounded GLP-1 option is appropriate, what risks to watch for, and what pharmacy path may fit your situation.
References
- 1.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. 2024.
- 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. 2024.
- 3.U.S. Food and Drug Administration. Saxenda (liraglutide) injection prescribing information. 2023.
- 4.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. 2023.
- 5.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. 2024.
- 6.U.S. Food and Drug Administration. FDA warns patients and health care professionals about compounded semaglutide. 2024.
- 7.U.S. Food and Drug Administration. FDA Drug Shortages Database. 2026.
- 8.U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers. 2024.
- 9.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- 10.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- 11.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
- 12.U.S. Department of Health and Human Services. Telehealth policy changes after the COVID-19 public health emergency. 2024.
- 13.Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. New England Journal of Medicine. 2023.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.



